Comparisons · checked 2026-08-07

How retatrutide compares

Retatrutide doesn't exist in isolation — it's one candidate in a fast-moving field. Here's how it stacks up against the medicines already licensed in the UK, and against the other pipeline drugs racing to catch up.

What retatrutide adds that dual agonists don't

The difference isn't just "one more receptor." Glucagon receptor activation engages pathways GLP-1/GIP dual agonists like tirzepatide don't directly touch.

Energy expenditure

Glucagon receptor activation raises resting energy use — a metabolic pathway that GLP-1 and GIP alone don't directly engage, and one proposed explanation for retatrutide's larger trial results.

Hepatic lipid oxidation

The same pathway increases fat breakdown in the liver, which lines up with the liver-fat results reported in the TRIUMPH trials.

Licensed and available in the UK today

Direct comparisons against the medicines you can actually get right now.

Retatrutide vs Mounjaro (tirzepatide)The closest mechanism available today — dual receptor agonist, ~21% weight loss in its own trials.→ Retatrutide vs Wegovy (semaglutide injection)The most established option, with the deepest cardiovascular outcomes evidence of the three.→ Retatrutide vs Ozempic (semaglutide, diabetes-branded)Same active ingredient as Wegovy, different indication and dose — and how that affects the comparison.→ Retatrutide vs Rybelsus (oral semaglutide)The only oral GLP-1 currently licensed in the UK — and why its results look very different to the injectables.→

Still in the pipeline — not available anywhere yet

Retatrutide isn't the only unlicensed candidate racing toward approval. Here's how it compares to the others.

Retatrutide vs CagriSemaNovo Nordisk's own next-generation candidate — already filed with the FDA, ahead of retatrutide in the regulatory queue.→ Retatrutide vs orforglipron (Foundayo)An injectable triple agonist vs an oral single-receptor pill — already FDA-approved in the US, still not licensed in the UK.→